JAML specific binding agents, antibodies, and uses related thereto
Disclosed are specific binding agents such as antibodies and chimera that bind to JAM-like protein. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods related thereto.
1. A chimeric JAML antibody that substantially prevents human JAML from binding CAR having CDR1, CDR2, and CDR3 heavy chain respective sequences of:
(SEQ ID NO:1) DYEMH;
amino acid residues 46 to 68 of SEQ ID NO: 19; and
(SEQ ID NO: 3) TRRRYYGSSYNWYFDV;
and having CDR1, CDR2, and CDR3 light chain respective sequences of:
(SEQ ID NO. 10) CRASENIYYSLAW;
(SEQ ID NO. 11) NANSLEDGVPSR; and
(SEQ ID NO. 12) YFCEQTYDVPLTFGAGT,
wherein the antibody does not substantially bind to JAMA or JAMC.
2. The chimeric antibody of claim 1 , wherein the antibody binds the D1 domain of JAML.
3. The chimeric antibody of claim 1 , wherein the antibody is a monoclonal antibody.
4. A pharmaceutical composition comprising an antibody of claim 1 .